ACTU — ACTUATE THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1652935 ·
Last close
$1.11
Market Cap
$26.56M
52W High
$3.43
52W Low
$1.03
ADV30
361,683
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,705,956 | -5,625,749 | 8,911,286 | 8,134,004 | 5,126,888 |
| Dec 2025 | 0 | — | -4,688,473 | -4,553,953 | 14,035,910 | 13,159,423 | 6,111,907 |
| Sep 2025 | 0 | — | -5,472,378 | -5,407,470 | 17,713,934 | 16,924,763 | 6,777,653 |
| Jun 2025 | 0 | — | -5,968,877 | -5,949,405 | 6,968,901 | 6,492,656 | 9,622,605 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,604,840
Investing CF
—
Financing CF
$23,849,439
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.11
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-160,233,450
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-21,516,328
Pretax Income TTM
$-21,536,577
Interest Exp TTM
$20,249
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -22,495,312 | -22,227,852 | 14,035,910 | 6,111,907 | — | -19,206,253 |
| Dec 2024 | 0 | -25,160,734 | -27,285,328 | 9,318,448 | 9,214,262 | — | -21,842,648 |
| Dec 2023 | 0 | -24,973,829 | -24,744,620 | 2,995,566 | 102,622,079 | — | -21,625,167 |
| Dec 2022 | 0 | -20,206,807 | -20,159,401 | 20,483,056 | 95,788,488 | — | -17,794,093 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.85
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | $26.48M | $0.06 | — |
| ATNM | Actinium Pharmaceuticals, Inc. | $26.26M | $0.84 | — |
| ABVC | ABVC BIOPHARMA, INC. | $26.26M | $1.01 | — |
| IGC | IGC Pharma, Inc. | $26.09M | $0.25 | — |
| QUCY | Quantum Cyber N.V. | $25.95M | $1.14 | — |
News headlines (Yahoo Finance, 1h cache)
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
2026-06-09 11:45 · Yahoo
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
2026-06-01 11:00 · Yahoo
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
2026-05-11 11:00 · Yahoo
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
2026-05-06 12:45 · Yahoo
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancr
2026-04-14 12:45 · Yahoo
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers
2026-03-24 11:00 · Yahoo
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
2026-03-09 12:45 · Yahoo
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
2026-03-04 22:00 · Yahoo
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
2026-02-24 13:45 · Yahoo
Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap dropped US$13m last week; Private equity firms bore the brunt
2026-02-04 12:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.